AZN.UK

13,638

-0.57%↓

GSK

1,799.5

-0.8%↓

PETS

198.3

-1.64%↓

AZN.UK

13,638

-0.57%↓

GSK

1,799.5

-0.8%↓

PETS

198.3

-1.64%↓

AZN.UK

13,638

-0.57%↓

GSK

1,799.5

-0.8%↓

PETS

198.3

-1.64%↓

AZN.UK

13,638

-0.57%↓

GSK

1,799.5

-0.8%↓

PETS

198.3

-1.64%↓

AZN.UK

13,638

-0.57%↓

GSK

1,799.5

-0.8%↓

PETS

198.3

-1.64%↓

Home・Aandelen Lijst・PureTech Health Plc

PureTech Health Plc

Gesloten

124 -2.36

Buy Sell

Overzicht

Wijziging aandelenprijs

24u

Huidig

Min

124

Max

126.6

Belangrijke statistieken
By Trading Economics
Inkomsten	-114M -45M
Verkoop	-2.2M 1.9M
K/W Sectorgemiddelde	9.754 78.892
EPS	-0.19
Winstmarge	-2,409.778
Werknemers	56
EBITDA	-148M -46M

Aanbevelingen
By TipRanks
Aanbevelingen	Buy
12 Maanden Prognose	+302.54% upside

Marktinformatie
By TradingEconomics
Marktkapitalisatie	-6.8M 306M
Vorige openingsprijs	126.36
Vorige sluitingsprijs	124

PureTech Health Plc Grafiek

Eerdere prestaties zijn geen betrouwbare indicator voor toekomstige resultaten.

Gerelateerd nieuws

24 dec 2025, 21:41 UTC

Acquisities, Fusies, Overnames

Nvidia to Buy Chip-Designer Groq for $20 Billion, CNBC Reports

26 dec 2025, 20:22 UTC

Marktinformatie

Oil Loses Ground On Russia-Ukraine Peace Efforts -- Market Talk

26 dec 2025, 20:13 UTC

Marktinformatie

U.S. Natural Gas Gains on Colder Weather Outlook -- Market Talk

26 dec 2025, 19:24 UTC

Acquisities, Fusies, Overnames

Nvidia's Groq Deal Is an Instagram Moment -- With 1 Big Risk -- Barrons.com

26 dec 2025, 17:45 UTC

Marktinformatie

U.S. Diesel Down on Lower Crude Prices, Freight-Sector Lull -- Market Talk

26 dec 2025, 15:52 UTC

Marktinformatie

Oil Futures Turn Lower After Steady Start -- Market Talk

26 dec 2025, 14:58 UTC

Marktinformatie

Silver, Gold Reach New Highs Amid Geopolitical Tension -- Market Talk

26 dec 2025, 14:41 UTC

Marktinformatie

U.S. Natural Gas Futures Look to End Week Higher -- Market Talk

26 dec 2025, 14:28 UTC

Marktinformatie

Dollar Indexes Flat as Yen Rally Wanes -- Market Talk

26 dec 2025, 13:47 UTC

Marktinformatie

Oil Futures Steady in Thin Holiday Trade -- Market Talk

26 dec 2025, 07:22 UTC

Marktinformatie

Comex Gold Futures' Strong Bullish Momentum in Play, Chart Shows -- Market Talk

26 dec 2025, 05:03 UTC

Marktinformatie

Malaysian Ringgit Likely to Face Pressure From Dollar Strength in 1Q -- Market Talk

26 dec 2025, 03:38 UTC

Marktinformatie

Global Equities Roundup: Market Talk

26 dec 2025, 03:38 UTC

Marktinformatie

Korean Won Strengthens, Supported by Verbal Interventions -- Market Talk

26 dec 2025, 02:44 UTC

Marktinformatie

Global Forex and Fixed Income Roundup: Market Talk

26 dec 2025, 02:44 UTC

Marktinformatie

Singapore Dollar Weakens Slightly on Likely Position Adjustments -- Market Talk

26 dec 2025, 01:39 UTC

Marktinformatie

China's Central Bank Signals Possibility of Easing Policy in Coming Months -- Market Talk

26 dec 2025, 01:14 UTC

Marktinformatie

Oil Edges Higher Amid Geopolitical Tensions -- Market Talk

26 dec 2025, 00:34 UTC

Marktinformatie

Yen Mostly Weakens Amid Risk-on Sentiment -- Market Talk

26 dec 2025, 00:15 UTC

Marktinformatie

Nikkei Gains 0.6%, Led by Tech, Videogame Stocks -- Market Talk

25 dec 2025, 23:42 UTC

Marktinformatie

Nikkei May Trade in Range; Yen in Focus -- Market Talk

25 dec 2025, 23:40 UTC

Marktinformatie

Gold Edges Higher Amid Geopolitical Risks -- Market Talk

25 dec 2025, 00:20 UTC

Acquisities, Fusies, Overnames

Nike Climb Boosts Dow, S&P 500 -- 2nd Update

24 dec 2025, 22:22 UTC

Acquisities, Fusies, Overnames

Nvidia, Groq Strike AI Tech Licensing Deal -- Barrons.com

24 dec 2025, 21:26 UTC

Acquisities, Fusies, Overnames

Nvidia to Buy Chip-Designer Groq for $20B, CNBC Reports

24 dec 2025, 19:35 UTC

Marktinformatie

Global Forex and Fixed Income Roundup: Market Talk

24 dec 2025, 19:35 UTC

Marktinformatie

Treasury Yields Decline Ahead of Christmas -- Market Talk

24 dec 2025, 19:09 UTC

Marktinformatie

Acquisities, Fusies, Overnames

Global Equities Roundup: Market Talk

24 dec 2025, 19:09 UTC

Marktinformatie

Acquisities, Fusies, Overnames

ServiceNow's Armis Acquisition Shouldn't Fuel Fears That Seat-Based Model Threatened -- Market Talk

24 dec 2025, 19:06 UTC

Marktinformatie

Oil Futures Little Changed in Light Pre-Holiday Trade -- Market Talk

Peer Vergelijking

Prijswijziging

PureTech Health Plc Prognose

Koersdoel

By TipRanks

302.54% opwaarts potentieel

12 Maanden Prognose

Gemiddelde 508 GBX 302.54%

Hoogste 508 GBX

Laagste 508 GBX

Gebaseerd op 1 Wall Street-analisten die 12-maands prijsdoelen bieden voor PureTech Health Plc - Dist. in de afgelopen 3 maanden.

Beoordelingsconsensus

By TipRanks

Buy

1 ratings

Buy

Hold

Sell

Gebaseerd op 1 analisten die aandelenratings hebben gegeven aan PureTech Health Plc - Dist in de afgelopen 3 maanden.

Financieel

Verkoop- en administratiekosten

Bedrijfskosten

Winst voor belastingen

Verkoop

Kosten van verkopen

Brutowinst op verkopen

Rente-uitgaven op schulden

EBITDA

Operationele winst

Over PureTech Health Plc

PureTech Health plc, engages in the development and commercialization of biotechnology and pharmaceutical solutions in the United States. The company is developing LYT-100, which is under Phase 2 stage, to treat idiopathic pulmonary fibrosis (IPF); and LYT-200, a IgG4 monoclonal antibody, currently under Phase 1/2 stage, targeting galectin-9 for treating solid tumors and hematological malignancies. It also develops SPT-300, an oral drug of allopregnanolone for the treatment of anxious depression; SPT-320, a novel prodrug of agomelatine for the treatment of generalized anxiety disorder; and SPT-348, a prodrug of a non-hallucinogenic neuroplastogen for the treatment of mood and other neuropsychiatric disorders. In addition, the company is developing hydrogels to enable the oral administration of peptide therapeutics in preclinical development. The company was incorporated in 2015 and is headquartered in Boston, Massachusetts.